RAPT Therapeutics Dividend
Dividend criteria checks 0/6
RAPT Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.9% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | -US$3.36 |
| Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?
Feb 21
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
Sep 12We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
May 10We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Feb 07We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Oct 12RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jan 25RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Oct 15RAPT Therapeutics (RAPT) skyrockets 100% on positive RPT193 data in early-stage atopic dermatitis study
Jun 14RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jun 08Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?
Mar 15We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth
Feb 15
RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year
Jan 18RAPT Therapeutics: Interesting Asset, But Doubtful History And Bad Market Reaction
Jan 08Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like
Dec 21The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares
Nov 23Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Nov 19RAPT Therapeutics tumbles 25% despite promising FLX475 data in multiple cancers
Nov 16Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if RAPT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RAPT's dividend payments have been increasing.
Dividend Yield vs Market
| RAPT Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (RAPT) | n/a |
| Market Bottom 25% (US) | 1.6% |
| Market Top 25% (US) | 4.8% |
| Industry Average (Biotechs) | 2.9% |
| Analyst forecast in 3 Years (RAPT) | 0% |
Notable Dividend: Unable to evaluate RAPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RAPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate RAPT's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RAPT has not reported any payouts.